Imagine a digital camera that can spot early signs of blindness caused by diabetes without needing a specialist to operate it. It uses smart software to take the perfect picture of the back of the eye and analyze it instantly. This means people can get screened at a local pharmacy instead of traveling to a hospital.
Current diabetic retinopathy screening is expensive and requires highly trained operators, creating a bottleneck in primary care and leaving millions of patients without early diagnosis.
A portable, low-cost retinal camera with integrated AI for automated image capture and diagnostic screening of diabetic retinopathy.
If you are a pharmacy chain dealing with a lack of specialized diagnostic tools for diabetic patients — this project developed a low-cost, automated camera that allows pharmacists to offer DR screening as easily as a blood glucose test.
If you are a primary care clinic dealing with long patient wait times for ophthalmologist referrals — this project developed a portable AI device that identifies diabetic retinopathy on-site to streamline patient flow.
If you are a distributor dealing with the high cost and training requirements of traditional fundus cameras in low-income markets — this project developed a portable, easy-to-use device for the 160 million people projected to have DR by 2045.
Based on available project data, the device is designed to be a low-cost alternative to current DR screening solutions which are described as expensive.
Yes, the solution is designed for relevance in both high-income markets like the US and Europe, as well as low- and middle-income countries like India.
The iScan project specifically includes activities to align the device with regulatory standards and a defined IP strategy.
No, the device features fully automated image capture and diagnostics, allowing healthcare professionals and pharmacists to use it with no prior training.
The project period is from 2023-01-01 to 2024-12-31, during which the company aims to clinically validate the solution.
The project is led by a single SME, OIVI AS from Norway, which holds 100% of the industry ratio. This lean structure suggests a fast-track commercialization approach where the company maintains full control over the IP and product development without the complexity of a multi-partner consortium.
Contact OIVI AS in Norway for licensing or partnership inquiries.
Contact us to explore integration of AI retinal screening into your healthcare network.
